Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.

Clicks: 300
ID: 106053
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #26 of 44 articles by views in BMC cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The BRAF gene encodes for the mutant BRAF protein, which triggers downstream oncogenic signaling in thyroid cancer. Since most currently available methods have focused on detecting BRAF mutations in tumor DNA, there is limited information about the level of BRAF mRNA in primary tumors of thyroid cancer, and the diagnostic relevance of these RNA mutations is not known.Sixty-two patients with thyroid cancer and non-malignant thyroid disease were included in the study. Armed with an ultrasensitive technique for mRNA-based mutation analysis based on a two step RT-qPCR method, we analysed the expression levels of the mutated BRAF mRNA in formalin-fixed paraffin-embedded samples of thyroid tissues. Sanger sequencing for detection of BRAF DNA was performed in parallel for comparison and normalization of BRAF mRNA expression levels.The mRNA-based mutation detection assay enables detection of the BRAF mRNA transcripts in a 10,000-fold excess of wildtype BRAF counterparts. While BRAF mutations could be detected by Sanger sequencing in 13 out of 32 malignant thyroid cancer FFPE tissue samples, the mRNA-based assay detected mutations in additionally 5 cases, improving the detection rate from 40.6 to 56.3%. Furthermore, we observed a surprisingly large, 3-log variability, in the expression level of the BRAF mRNA in FFPE samples of thyroid cancer tissue.The expression levels of BRAF mRNA was characterized in the primary tumors of thyroid cancer using an ultrasensitive mRNA-based mutation assay. Our data inspires further studies on the prognostic and diagnostic relevance of the BRAF mRNA levels as a molecular biomarker for the diagnosis and monitoring of various genetic and malignant diseases.
Reference Key
tran2020evaluationbmc Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tran, Tien Viet;Dang, Kien Xuan;Pham, Quynh Huong;Nguyen, Ung Dinh;Trinh, Nhung Thi Trang;Hoang, Luong Van;Ho, Son Anh;Nguyen, Ba Van;Nguyen, Duc Trong;Trinh, Dung Tuan;Tran, Dung Ngoc;Orpana, Arto;Stenman, Ulf-Håkan;Stenman, Jakob;Ho, Tho Huu;
Journal BMC cancer
Year 2020
DOI
10.1186/s12885-020-06862-w
URL
Keywords
diagnosis thyroid cancer braf mutation mrna mutation assay

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.